Current therapeutic interventions designed to target the inhibition of the transforming growth factor-β (TGF-β) signaling pathway have shown promising efficacy in ameliorating pulmonary fibrosis [30]. This evidence concerns the gene TGFB1 and pulmonary fibrosis.